Lebrikizumab improves atopic dermatitis and quality of life in patients with moderate-to-severe atopic dermatitis previously treated with dupilumab: Results from the ADapt trial
Recommended Citation
Silverberg JI, Ackerman L, Bagel J, Stein Gold LF, Blauvelt A, Rosmarin D, Chovatiya R, Zirwas M, Yosipovitch G, Waibel J, Murase JE, Lockshin B, Weisman J, Atwater AR, Harris C, Proper J, Silk M, Pierce E, Buziqui Piruzeli ML, Montmayeur S, Schuster C, Zhong J, Rueda MJ, Pillai S, Simpson E. Lebrikizumab improves atopic dermatitis and quality of life in patients with moderate-to-severe atopic dermatitis previously treated with dupilumab: Results from the ADapt trial. J Clin Aesthet Dermatol 2025; 18(Suppl 1):S40.
Document Type
Conference Proceeding
Publication Date
11-12-2025
Publication Title
J Clin Aesthet Dermatol
Abstract
Introduction: ADapt (NCT05369403), an open-label, Phase 3b, 24-week study, evaluated the efficacy and safety of lebrikizumab (LEB) in patients with moderate-to-severe atopic dermatitis (AD) previously treated with dupilumab (DUPI). Patients must have discontinued DUPI due to inadequate response (non-response, partial response, or loss of response), intolerance or an adverse event (AE), or other reasons. Methods: Four or more weeks after discontinuing DUPI, patients received a 500mg LEB loading dose at baseline and at Week 2 followed by 250mg every two weeks through Week 16 (Q2W). At Week 16, responders (IGA 0 or 1 with ≥ 2-point improvement [IGA0,1] or EASI75 [primary endpoint]) received LEB 250mg once every four weeks (Q4W); other patients continued with 250mg Q2W. Q2W and Q4W data were pooled and analyzed as-observed and with nonresponder/multiple imputation (NRI/MI). Results: Among 86 enrolled patients, 56 percent discontinued DUPI due to inadequate response, 16 percent due to intolerance/AEs to DUPI, and 28 percent for other reasons. For all patients, at Weeks 16 and 24, respectively, proportions of patients achieving: 1) EASI75: 57.4 percent and 60.0 percent, as-observed; 50.7 percent and 52.8 percent NRI/MI; 2) IGA0,1: 38.7 percent and 38.2 percent, as-observed; 35.6 percent and 36.8 percent, NRI/MI; 3) Face-IGA 0: 42 percent and 49 percent, as-observed; 4) Pruritus NRS ≥ 4-point improvement 53.2 percent and 61.5 percent as-observed; 48.8 percent and 47.9 percent NRI/MI; and 5) DLQI ≥ 4-point improvement 83.0 percent and 83.0 percent as-observed. The safety profile was consistent with other LEB Phase 3 trials. Four patients who discontinued DUPI due to conjunctivitis did not report conjunctivitis with LEB. Additionally, 3.5 percent of patients reported treatment-emergent conjunctivitis. Conclusion: In DUPI-experienced patients, treatment of moderate-to-severe AD with LEB resulted in meaningful improvements in skin clearance, itch, and quality of life.
Volume
18
Issue
Suppl 1
First Page
S40
